Barbier Charlotte Ebeling, Rorsman Fredrik, Eriksson Lars-Gunnar, Sangfelt Per, Sheikhi Reza, Vessby Johan, Nyman Rickard
Department of Surgical Sciences, Section of Radiology, Uppsala University, Uppsala, Sweden.
Department of Medical Sciences, Section of Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden.
Acta Radiol Open. 2020 Oct 13;9(10):2058460120964074. doi: 10.1177/2058460120964074. eCollection 2020 Oct.
Portomesenteric vein thrombosis may be life-threatening due to bowel ischemia caused by venous stasis, or variceal bleeding caused by portal hypertension.
To evaluate the effectiveness and safety of recanalization combined with transjugular intrahepatic portosystemic shunt in acute and chronic portomesenteric vein thrombosis in patients with and without liver cirrhosis.
21 consecutive patients (5 women, 16 men; mean 48 years) with portomesenteric vein thrombosis (8 acute, 13 chronic) treated at the Interventional Radiology department between March 2014 and September 2018 were retrospectively reviewed. The main portal vein was completely obliterated and the portomesenteric vein thrombosis extended into the superior mesenteric vein in all patients. The portomesenteric vein thromboses were recanalized transhepatically, a transjugular intrahepatic portosystemic shunt was inserted, thrombectomy was performed in acute portomesenteric vein thrombosis, and angioplasty with or without additional stenting was performed in chronic portomesenteric vein thrombosis.
Recanalization was successful in 8/8 patients (100%) with acute portomesenteric vein thrombosis, and in 11/13 patients (85%) with chronic portomesenteric vein thrombosis. In 12 patients, blood flow was restored in one session. Several sessions were more frequently needed in patients with acute portomesenteric vein thrombosis compared to those with chronic portomesenteric vein thrombosis ( = 0.003). Re-occlusion occurred and was recanalized in 10/19 patients and was more frequent in patients with chronic ( = 8/11) than on those with acute ( = 2/8) portomesenteric vein thrombosis ( = 0.04). Adverse events occurred in five patients. There was no 30-day mortality.
Recanalization and insertion of a transjugular intrahepatic portosystemic shunt is safe and effective in patients with acute and chronic portomesenteric vein thrombosis with or without cirrhosis. Recanalization was more likely to stay patent in acute compared with chronic portomesenteric vein thrombosis.
门静脉肠系膜静脉血栓形成可能因静脉淤滞导致肠缺血或门静脉高压导致静脉曲张出血而危及生命。
评估再通联合经颈静脉肝内门体分流术治疗肝硬化和非肝硬化患者急慢性门静脉肠系膜静脉血栓形成的有效性和安全性。
回顾性分析2014年3月至2018年9月在介入放射科接受治疗的21例连续门静脉肠系膜静脉血栓形成患者(5例女性,16例男性;平均48岁)(8例急性,13例慢性)。所有患者的门静脉主干完全闭塞,门静脉肠系膜静脉血栓延伸至肠系膜上静脉。经肝对门静脉肠系膜静脉血栓进行再通,插入经颈静脉肝内门体分流术,对急性门静脉肠系膜静脉血栓形成患者进行血栓切除术,对慢性门静脉肠系膜静脉血栓形成患者进行血管成形术(有或无额外支架置入)。
8例急性门静脉肠系膜静脉血栓形成患者中有8例(100%)再通成功,13例慢性门静脉肠系膜静脉血栓形成患者中有11例(85%)再通成功。12例患者一次恢复血流。与慢性门静脉肠系膜静脉血栓形成患者相比,急性门静脉肠系膜静脉血栓形成患者更常需要多次治疗(P = 0.003)。19例患者中10例发生再闭塞并再次再通,慢性门静脉肠系膜静脉血栓形成患者(8/11)比急性门静脉肠系膜静脉血栓形成患者(2/8)更频繁(P = 0.04)。5例患者发生不良事件。无30天死亡率。
对于有或无肝硬化的急慢性门静脉肠系膜静脉血栓形成患者,再通联合经颈静脉肝内门体分流术是安全有效的。与慢性门静脉肠系膜静脉血栓形成相比,急性门静脉肠系膜静脉血栓形成的再通更可能保持通畅。